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Abstract
Background: Worldwide, lung cancer kills more people than breast, colon and prostate cancer combined.
Alterations in macrophage number and function during lung tumorigenesis suggest that these immune effector
cells stimulate lung cancer growth. Evidence from cancer models in other tissues suggests that cancer cells actively
recruit growth factor-producing macrophages through a reciprocal signaling pathway. While the levels of lung
macrophages increase during tumor progression in mouse models of lung cancer, and high pulmonary
macrophage content correlates with a poor prognosis in human non-small cell lung cancer, the specific role of
alveolar macrophages in lung tumorigenesis is not clear.
Methods: After culturing either an immortalized lung macrophage cell line or primary murine alveolar
macrophages from naïve and lung-tumor bearing mice with primary tumor isolates and immortalized cell lines, the
effects on epithelial proliferation and cellular kinase activation were determined. Insulin-like growth factor-1 (IGF-1)
was quantified by ELISA, and macrophage conditioned media IGF-1 levels manipulated by IL-4 treatment,
immuno-depletion and siRNA transfection.
Results: Primary macrophages from both naïve and lung-tumor bearing mice stimulated epithelial cell
proliferation. The lungs of tumor-bearing mice contained 3.5-times more IGF-1 than naïve littermates, and media
conditioned by freshly isolated tumor-educated macrophages contained more IGF-1 than media conditioned by
naïve macrophages; IL-4 stimulated IGF-1 production by both macrophage subsets. The ability of macrophage
conditioned media to stimulate neoplastic proliferation correlated with media IGF-1 levels, and recombinant IGF-1
alone was sufficient to induce epithelial proliferation in all cell lines evaluated. Macrophage-conditioned media and
IGF-1 stimulated lung tumor cell growth in an additive manner, while EGF had no effect. Macrophage-derived
factors increased p-Erk1/2, p-Akt and cyclin D1 levels in neoplastic cells, and the combined inhibition of both MEK
and PI3K ablated macrophage-mediated increases in epithelial growth.
Conclusions: Macrophages produce IGF-1 which directly stimulates neoplastic proliferation through Erk and Akt
activation. This observation suggests that combining macrophage ablation therapy with IGF-1R, MEK and/or PI3K
inhibition could improve therapeutic response in human lung cancer. Exploring macrophage-based intervention
could be a fruitful avenue for future research.
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Lung cancer is a worldwide epidemic. In 2009, nearly
160,000 people died from lung cancer in the U.S. alone.
The five-year survival rate slightly increased from 13%
to 15% over the last 25 years, mainly due to limited
early cancer detection and minor improvements in ther-
apy [1]. Non-small cell lung cancer (NSCLC) is the
most common form of the disease, and adenocarcinoma
(AC) of the distal lung the most frequently diagnosed
subtype [2]. Persistent lung inflammation due to cigar-
ette smoke and related pulmonary comorbidities such as
chronic obstructive pulmonary disease increases the life-
time risk of developing lung cancer [3], which can be
partially alleviated by long-term anti-inflammatory drug
therapy [4,5]. Therefore, delineating the causal relation-
ship between inflammation and lung carcinogenesis may
lead to earlier diagnosis and more effective treatment.
To understand how chronic lung inflammation pro-
motes the growth of lung cancer, it is important to
examine communication between pulmonary epithelial
cells and inflammatory effector cells such as alveolar
macrophages. Macrophages are the most abundant type
of immune cell in a healthy lung [6], and alveolar
macrophage numbers increase dramatically as chronic
diseases like NSCLC progress [7-9]. Macrophages infil-
trate most solid cancers, including NSCLC, and lung
cancer patients display an inverse relationship between
macrophage infiltration and survival [7,9]. Local envir-
onmental stimuli modulate macrophage function, a pro-
cess referred to as macrophage activation or
polarization. Classical macrophage activation arises in
response to tissue damage signals, whereas alternative
activation is associated with wound healing and cancer
progression [10,11]. In experimental mouse models of
NSCLC, alveolar macrophages become alternatively acti-
vated within weeks of lung tumor initiation [6]. Chemi-
cal depletion of macrophages delays lung tumorigenesis,
while chemically-induced chronic inflammation greatly
increases lung macrophage content and stimulates lung
tumor growth [12].
Although the mechanisms by which recruited macro-
phages contribute to lung AC growth and progression
have not been delineated, the reciprocal growth factor
interaction between macrophages and breast cancer
cells suggests one possibility [13,14]. In mouse models
of invasive breast cancer, macrophage-secreted epider-
mal growth factor (EGF) stimulates growth and migra-
tion of mammary tumor cells, which in turn secrete
colony stimulating factor-1 (CSF-1) to recruit additional
macrophages to the tumor site [13]. This reciprocal
growth factor signaling cascade can induce the migra-
tion of neoplastic cells from the primary breast tumor
site into systemic circulation, dramatically increasing the
potential for metastatic colonization [15]. Unlike breast
cancer, little is known regarding the contribution of
macrophage-derived growth factors to lung cancer
growth.
Compared to macrophages in other tissues, the alveo-
lar macrophage is fairly unique due to the monocyte dif-
ferentiation cytokines present in the lung
microenvironment. Specifically, granulocyte-monocyte
colony stimulating factor (GM-CSF) is highly expressed
while local concentrations of CSF-1 are typically low.
High levels of GM-CSF induce the differentiation of
blood monocytes into dendritic-like cells, instead of the
more traditional macrophage-like fate directed by CSF-1
[9]. Consistent with these observations, alveolar macro-
phages more closely resemble immature dendritic cells
than do macrophages isolated from other tissues [16].
Because of these distinct differences in morphology and
function, pulmonary macrophages may stimulate lung
cancer proliferation by providing growth factors differ-
e n tt h a nt h o s ed e s c r i b e di nb r e a s ta n do v a r i a nc a n c e r .
While cultured lung AC cells produce several macro-
phage chemoattractants, including IL-1b and GM-CSF
[17,18], there are few reports of any reciprocal growth
factor exchange between primary alveolar macrophages
and NSCLC [18]. Although the specific factors have not
been clearly identified, tumor growth may be stimulated
through common downstream signaling mechanisms
such as increased Erk1/2 activity, as Erk1/2 is hyper-
activated in NSCLC [19,20]. Thus, in addition to identi-
fying lung macrophage-derived tumor growth factors,
targeting signaling pathways common to neoplastic
growth may also be therapeutically beneficial.
Nearly 25% of NSCLCs contain activating mutations
in KRAS, resulting in growth stimulation through
increased Erk1/2 and Akt activities [21,22]. Kras-
mediated activation of extracellular-regulated kinase
kinase (MEK) and phosphoinositide-3 kinase (PI3K)
directly increases proliferation and cell survival through
transcriptional regulation, increased cell cycle progres-
sion, and inhibition of pro-apoptotic factors [20,23].
Although Kras signals through multiple downstream
effectors, experimental studies have shown that lung
tumors containing mutated Kras are clearly dependent
on cellular kinases such as Erk1/2 and Akt for contin-
ued growth and survival [24]. Mutations in Kras are suf-
ficient to initiate lung tumorigenesis [25], and
chronically high lung macrophage content greatly accel-
erates the growth and progression of this disease [5,12].
Many growth factors stimulate Erk1/2 and Akt activity
in healthy tissues; among these, insulin-like growth fac-
tor 1 (IGF-1) is associated with neoplastic growth and
expansion [26,27]. In mouse lungs, IGF-1 was originally
identified as an alveolar macrophage-derived growth
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tion has been observed in models of environmental lung
injury [30]. IGF-1 receptor inhibition is currently under
intensive clinical investigation, and early reports show
therapeutic promise in some NSCLC patients [12,27].
Therefore, IGF-1 could be one candidate by which lung
macrophages accelerate the growth of lung tumors.
We sought to determine if chronic inflammation
drives lung tumorigenesis, in part, by recruiting and
polarizing alveolar macrophages, which in turn produce
IGF-1 that directly stimulates neoplastic growth. Since
both healthy and tumor-bearing lungs contain dozens of
unique resident and infiltrating cell types [31], we co-
cultured primary and immortalized mouse lung cells
with macrophages, and demonstrated increased epithe-
lial proliferation after exposure to macrophages in a
simplified in vitro system. Such macrophage co-culture
stimulated Erk1/2 and Akt activation, increased cyclin
D1 expression, and enhanced the proliferation of neo-
plastic lung cells; the inhibition of both MEK and PI3K
could block this macrophage-augmented tumor cell
growth. IGF-1 was detected in lung lavage fluid and
macrophage conditioned media, and was significantly
elevated in tumor-bearing lungs and tumor-educated
macrophage-conditioned media. Our findings demon-
strate that macrophages recruited to the chronically
inflamed lung have an enhanced ability to directly aug-
ment neoplastic growth, suggesting that specifically tar-
geting tumor-associated macrophages, in addition to
macrophage-derived growth factors, may be beneficial
for future cancer therapy.
Results
Macrophage conditioned media profoundly stimulates
the anchorage-independent growth of lung tumor cells
Despite the correlation between lung macrophage con-
tent and lung tumor growth, the direct contribution of
alveolar macrophages to lung tumor growth is unclear
[6,7,13]. Media conditioned by an immortalized lung
macrophage cell line, MH-S, has been previously
reported to stimulate the migration of lung epithelial
cells harboring Kras mutations [18]. To determine if
MH-S conditioned media directly stimulates neoplastic
growth, we first evaluated neoplastic colony formation
and cell number after long-term conditioned media
exposure. In both the classic model of anchorage-inde-
pendent neoplastic growth on soft agar (Figure 1A-C),
and colonization on new ultra-low adherence, neu-
trally-charged plastic (Figure 1D-F), macrophage-con-
ditioned media potently stimulated the proliferation of
two Kras mutant lung tumor-derived cell lines (LM2
and JF32). Thus, macrophages secrete soluble mole-
cules capable of greatly stimulating neoplastic colony
formation and proliferation in vitro, which may shed
light on the role of macrophage recruitment to lung
cancer in vivo.
Naïve and tumor-educated primary macrophage co-
culture stimulates the proliferation of neoplastic and non-
neoplastic pulmonary epithelial cells
The relative ability of naïve vs. tumor-educated alveolar
macrophages to directly stimulate lung epithelial cell
proliferation not been reported. To determine if macro-
phages from the lungs of tumor-bearing mice could
directly stimulate neoplastic cell growth in a co-culture
system, neoplastic LM2 cells were co-cultured with
bronchoalveolar lavage (BAL) macrophages (MØ) iso-
lated from tumor-bearing mice, and monolayer growth
was assessed (Figure 2A). Growth in standard tissue cul-
ture conditions measures proliferation per se, and not
cell motility or the requirement for solid support, and
permits the evaluation of non-neoplastic epithelial cells
which do not proliferate in anchorage-independent sys-
tems. LM2 cell number significantly increased with BAL
macrophage co-culture at 48 (2.3 vs. 4.1-fold) and 72
hrs (3.5 vs. 7.5-fold) (Figure 2A). As 72 hrs of macro-
p h a g ec o - c u l t u r er e s u l t e di n≥ 2-times more tumor
cells, this time point was used in subsequent experi-
ments. To determine if tumor-educated macrophages
stimulated neoplastic growth more effectively than
naïve, BAL macrophages from either naïve or tumor-
bearing mice were co-cultured with neoplastic LM2
(Figure 2B) and JF32 (Figure 2C) cells. LM2 growth was
equally stimulated by both naïve and tumor-educated
BAL macrophages, while the growth of JF32 cells was
enhanced slightly upon co-culture with tumor-educated
BAL macrophages (Figure 2C). To determine if primary
alveolar macrophages also stimulated the proliferation of
non-tumor cells, the non-neoplastic E10 cell line was
co-cultured with naïve and tumor-educated BAL macro-
phages. Both macrophage types increased E10 cell num-
ber 3.5-fold (Figure 2D) when maintained in serum-free
conditions; only tumor-educated macrophages stimu-
lated E10 proliferation when cultured in the presence of
serum (Figure 2E). Both types of primary macrophages
equally stimulated LM2 proliferation in the presence of
serum, though the magnitude was reduced when com-
pared to serum-free co-culture (data not shown).
To determine if MH-S macrophages could recapitulate
the effects of primary alveolar macrophages in this in
vitro model, we co-cultured MH-S macrophages with
both neoplastic and non-neoplastic lung epithelial cells.
MH-S co-culture increased the growth rate of all pul-
monary epithelial cell lines similar to co-culture with
tumor-educated BAL macrophages (Figure 2B-E). These
results indicate that primary lung macrophages produce
diffusible signals which can augment the proliferation of
both non-neoplastic and neoplastic cells in vitro.
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primary lung macrophages slightly enhances this ability
to stimulate epithelial proliferation, an effect similar to
co-culture with MH-S macrophages.
Macrophage co-culture stimulates epithelial proliferation
through kinase activation
Since MH-S macrophages and tumor-educated primary
macrophages stimulated epithelial proliferation to a
similar degree, MH-S macrophages were used to eluci-
date the mechanisms of increased epithelial proliferation.
Because Kras pathways are commonly hyper-activated in
lung tumorigenesis [22,23], and the tumorigenic lines
examined herein contain Kras mutations, activities of
downstream mediators Erk and Akt were examined.
Cytosolic Raf functionally links the Erk and Akt path-
ways; activated Akt can phosphorylate cRaf at S259, pla-
cing Erk regulation downstream of Akt activation [32,33].
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Figure 1 Anchorage-independent neoplastic lung cell line proliferation is augmented by macrophage conditioned media. A: Neoplastic
LM2 or JF32 cells were cultured on 0.75% agarose in serum-free media containing 0.5% BSA (Control), or in similar media conditioned by MH-S
macrophages (+ MH-S CM). B-C: LM2 or JF32 colonies from (A) were quantified under 20× magnification, and means + SD from duplicate wells
plotted from three independent experiments (n = 6). D: Neoplastic LM2 or JF32 cells were cultured on ultra-low attachment culture plates, and
treated as above. E-F: LM2 or JF32 cells from (D) were quantified and mean + SD of live cell numbers plotted from three independent
experiments (n = 3). * P < 0.05, ** P < 0.01 and *** P < 0.001 versus control by student’s unpaired t-test.
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S259 in all three cell lines, resulting in significantly higher
levels of p-cRaf (Figure 3A-C). The smaller (~74 kDa) p-
cRaf isoform was most highly abundant and its phos-
phorylation significantly increased with macrophage co-
culture in the LM2 and E10 cells, but a larger (~100 kDa)
isoform was heavily phosphorylated at the expense of the
74 kDa isoform in neoplastic JF32 cells (Figure 3A). The
74 kDa isoform was the most abundant in total cRaf
immunoblots from all three cell lines.
MH-S co-culture significantly increased the levels of
active Erk1/2 (p-Erk) in LM2 and JF32 cells, as well as
non-neoplastic E10 cells, when normalized either to total
Erk (panErk) or b-actin levels (Figure 3A, D and 3E),
which correlates with the observed increases in prolifera-
tion (Figure 2). E10 cells expressed lower basal p-Erk/
panErk vs. the neoplastic cell lines, consistent with pre-
vious observations [21]. Total Erk remained unchanged
in both neoplastic cell lines, while macrophage co-culture
caused Erk2 (42 kDa) to nearly disappear in the E10 cells,
with little effect on Erk1 (Figure 3A, D and 3E). Activated
Akt (p-Akt) levels rose significantly in both neoplastic
cell lines when normalized to either total Akt (panAkt)
or b-actin, but macrophage co-culture caused both p-Akt
and panAkt levels to rise to similar extents in E10 cells
(Figure 3A and 3F). When p-Akt was normalized to
panAkt expression, there was no change in E10 cells with
MH-S co-culture (Figure 3F). Total Akt expression
increased slightly in LM2 cells but decreased in JF32 cells
(Figure 3A). When normalized to b-actin, p-Akt levels
significantly increased upon MH-S co-culture in all three
cell lines (Figure 3A and 3G).
Increased p-S473 Akt content suggests increased enzy-
matic activity, which can be confirmed by enhanced
phosphorylation of downstream substrates. To deter-
mine if macrophage co-culture increases Akt activity, we
measured levels of p-GSK-3b, a known target of Akt
[32]. Consistent with the elevation in p-Akt, MH-S co-
culture significantly increased p-GSK-3b in both LM2
and E10 cells and trended towards an increase in JF32
cells (Figure 3A and 3H); panGSK-3b levels were
unchanged (data not shown). Phospho-S259 cRaf is
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Figure 2 Lung cell proliferation is accelerated by alveolar macrophage co-culture. A: Neoplastic LM2 cells were cultured alone (Δ) or with
primary BAL macrophages from tumor-bearing mice (●) in serum-free media. B-D: (B) LM2, (C) JF32 and (D) E10 cell lines were co-cultured with
BAL macrophages (MØ) from naïve (grey bars) or tumor-bearing (black bars) mice, or the MH-S macrophage cell line (green bars) for 72 hrs in
serum-free media. E: E10 cells were co-cultured as in (D), but in media containing 10% serum. Epithelial cells cultured in the absence of
macrophages were controls (blue bars). Proliferation was determined as described, and mean ± SD pooled from at least 3 independent
experiments plotted as fold-change from control (normalized to 1). * P < 0.05, ** P < 0.01 and *** P < 0.001 versus control; # P < 0.01, ## P <
0.001 between (A) conditions at the indicated time points, or (C, E) between proliferation induced by primary macrophage source (naïve vs.
tumor-bearing mice).
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increased in all three cell lines with macrophage co-cul-
ture (Figure 3A-C). Together, the observed increases in
epithelial proliferation and the known roles for Erk and
Akt in neoplastic lung cell division suggest that macro-
phage co-culture stimulates lung cell proliferation
through increased Erk and Akt activity [34].
Combined inhibition of MEK and PI3K abrogates
macrophage stimulation of neoplastic growth
Erk and Akt regulate both proliferation and resistance to
apoptotic cell death, are more active in lung tumors
than in normal tissue [21,35], and were activated with
macrophage co-culture. Since combined MEK and PI3K
inhibition slowed mutant Kras-driven lung tumor
growth in vivo [25], we determined whether selective
inhibition of MEK and PI3K affected macrophage-stimu-
lated proliferation in these Kras mutant lung tumor cell
lines. Selective inhibition of either MEK (by U0126) or
PI3K (by LY294002) significantly decreased basal prolif-
eration, and blocked growth stimulated by macrophage
co-culture to different extents in LM2 and JF32 cells
(Figure 4A and 4B, respectively). Only the combined
inhibition of both kinases ablated the stimulatory effect
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Figure 3 MH-S co-culture increases activation of growth-associated kinases. A: LM2, JF32 and E10 cells were plated in triplicate, and
cultured alone (-) or with MH-S macrophages (+). Protein homogenates from whole cell lysates were probed for expression of phospho-cRaf (p-
cRaf), total c-Raf (pan-cRaf), phospho-Erk1/2 (p-Erk), total Erk1/2 (panErk), phospho-Akt (p-Akt), total Akt (panAkt), phospho-GSK-3b and b-actin. B-
H: Band densitometry was determined as described, and data plotted as percent induction normalized to control intensity. Densitometry
presented as mean + SEM from n = 3 replicates combined, and is representative of 3 independent experiments. * P < 0.05, ** P < 0.01 versus
control culture (-MH-S) by unpaired t-test.
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(U0 + LY, Figure 4). Kinase inhibitors were applied at
concentrations reported to be cytostatic and not cyto-
toxic [34,36,37], and none of these treatments signifi-
cantly increased LM2 or JF32 cell death (data not
shown). These results suggest that both the MEK and
PI3K pathways must be blocked to effectively inhibit
macrophage-stimulated neoplastic growth.
Macrophage conditioned media contains 3-10 kDa factors
which stimulate neoplastic proliferation
Macrophages produce numerous cytokines, eicosanoids
and other soluble factors depending upon tissue location
and environmental stimuli [4,18], any number of which
could be responsible for the observed neoplastic growth
stimulation described above. Media conditioned by pri-
mary BAL macrophages (MØCM) stimulated the prolif-
eration of LM2 cells, albeit to a lesser extent than
primary macrophage co-culture (Figure 5 “Total” vs.
Figure 2B). When size-fractionated MØCM was added
to LM2 cells, molecules between 3 and 10 kDa stimu-
lated LM2 growth to the greatest extent (Figure 5).
Thus, factors of this size mediated the majority of
MØCM effects on LM2 growth. Alveolar macrophages
produce numerous growth factors in this size range,
including IGF-1, GM-CSF and EGF [11,18]. To further
narrow down the list of possible candidates, an in silico
analysis was performed for each fraction size as
described in Materials and Methods. The resulting data
points were separately fit for each fraction size to the
general equation y = y0 + a(1-e
-bx) as described, with
regression r
2 = 0.997, 0.842 and 0.918 for the > 3, > 10
and > 30 kDa fractions, respectively. From regression
analysis, the responsible factor(s) appeared to be 7.23-
10.8 kDa in size, suggesting that growth factors such as
IGF-1 (7.5 kDa) may be responsible for the MØCM-sti-
mulated neoplastic proliferation.
Macrophage-conditioned media IGF-1 levels correlate to
effects on neoplastic proliferation
IGF-1 has a well-established role in the metastasis of
cancer cells in vivo, as well as stimulating growth in
vitro [27], and alveolar macrophages produce high levels
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Figure 5 3-10 kDa molecules in MØCM stimulate epithelial
proliferation. Neoplastic LM2 cells were cultured for 72 hrs after
the addition of fresh media (Control, white bars) or MØCM
(+MØCM, black bars), separated by size (kDa) into the fractions
indicated. Relative cell number was determined by MTS and mean
+ SD plotted as fold-change from control cultures, normalized for
each size fraction. Data was pooled from n = 3 independent
experiments. * P < 0.01 and ** P < 0.001 versus control within each
fraction group, and # P < 0.01, ## P < 0.001 versus total
(unfractionated) MØCM by 2-way ANOVA.
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[30]. While alveolar macrophages are an important com-
ponent of the chronic inflammatory milieu responsible
for promoting lung tumorigenesis, IGF-1 has not been
examined as a possible connection between macrophage
recruitment and lung cancer progression. BALF from
tumor-bearing lungs contained 3.5-times more IGF-1
than BALF from naïve mice, while EGF levels were
unchanged (Figure 6A). Even after normalizing to total
BALF protein levels, BALF IGF-1 was significantly
higher in tumor-bearing animals than naïve controls
(1.81 ± 0.33 vs. 0.95 ± 0.36 pg IGF-1/ug BALF protein,
respectively, P < 0.01, mean ± SD), suggesting that more
IGF-1 is produced in the lungs of tumor-bearing mice.
Measurement of IGF-1 levels in MØCM from primary
naïve and tumor-educated BAL macrophages showed
that tumor-educated macrophages produced signifi-
cantly more IGF-1 than naïve macrophages (Figure 6B,
grey bars). IL-4 potently stimulates alternative macro-
phage activation, and is more abundant in tumor-bear-
ing lungs than naïve [38]. Alternative macrophage
polarization is associated with tumorigenesis [6] and
increased macrophage IGF-1 production [39]. Therefore,
IL-4 was added to wells containing primary naïve and
tumor-educated BAL macrophages to determine if alter-
native activation could increase IGF-1 production in
either macrophage group. Both naïve and tumor-edu-
cated macrophages produced significantly more IGF-1
after IL-4 treatment; tumor-educated macrophages more
than doubled IGF-1 output compared to naïve samples
(Figure 6B, green bars). MH-S macrophages produced
20-times more IGF-1 than either non-neoplastic or neo-
plastic lung cell lines, and all three cell lines produced
only trace amounts (< 2 pg/mL) of EGF (Figure 6E).
In order to determine whether the growth effects of
MØCM from samples generated in Figure 6B correlated
with their IGF-1 content, MØCM was added to neoplas-
tic LM2 cells. IL-4 stimulated naïve and tumor-educated
MØCM significantly augmented LM2 proliferation (Fig-
ure 6C, green bars), with IL-4 treated tumor-educated
MØCM being the most potent. MØCM from untreated
tumor-educated macrophages did not stimulate LM2
growth significantly more than untreated naïve MØCM
(Figure 6C, grey bars), corresponding to previous co-cul-
ture results (Figure 2B). As the growth-stimulating abil-
ity of MØCM appeared to correlate to media IGF-1
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Page 8 of 20levels, the levels of IGF-1 present were plotted against
the fold-change in LM2 cell number after MØCM addi-
tion (Figure 6D). The correlation between IGF-1 levels
and neoplastic growth stimulation was highly significant
(p < 0.001), indicating that MØCM IGF-1 levels were
directly related to the ability of MØCM to stimulate
neoplastic proliferation.
IGF-1 stimulates lung epithelial cell proliferation and is
additive with MØCM
While IGF-1 levels correlated strongly with the ability of
MØCM to stimulate neoplastic growth, IGF-1 induced
proliferation of these non-neoplastic and neoplastic
mouse lung cell lines has not been demonstrated.
Recombinant mouse IGF-1 or MH-S macrophage-condi-
tioned media was sufficient to stimulate the proliferation
of neoplastic LM2, JF32 and E9 cells and non-neoplastic
E10 cells (Figure 7A-D). The degree of growth stimu-
lated by 50 ng/mL IGF-1 was similar to that of MØCM
in each line (Figure 7A-D). These results confirm that
IGF-1 alone can stimulate the growth of long-estab-
lished neoplastic and non-neoplastic cell lines, as well as
cells isolated more recently from primary mouse lung
tumors (JF32), consistent with previous reports on
human cancer cell lines [27]. In order to determine any
relevant role of EGFR in mediating macrophage-stimu-
lated tumor cell proliferation in these cell lines, recom-
binant mouse EGF was added at 2 ng/mL. This is
roughly 500-times the reported EC50 for growth stimula-
tion and 20-times higher than levels found in the BALF
from tumor-bearing animals (Figure 6A). EGF had no
significant effect on tumor cell proliferation when added
alone, and did not significantly affect the ability of either
IGF-1 or MØCM to stimulate neoplastic growth (Figure
7E, F). This is not surprising in view of recent studies
showing that EGFR inhibitors do not inhibit growth of
lung cells with KRAS mutations [40].
As IGF-1 was sufficient to induce neoplastic prolifera-
tion, we determined whether the IGF-1 and MØCM
growth effects were additive. A dose of 50 ng/ml IGF-1
stimulated neoplastic growth to a similar extent as
MØCM (Figure 7A-D); 2 ng/mL IGF is the reported
EC50 for IGF-1 stimulated proliferation in vitro as well
as the concentration detected in the BALF of tumor-
bearing mice in vivo (Figure 6A). IGF-1 dose-depen-
dently stimulated the proliferation of both LM2 and
JF32 cells, and augmented the growth-stimulating effects
of MØCM when added in combination. To determine if
IGF-1R signaling mediates both IGF-1 and MØCM sti-
mulation, lung cancer cells were pre-treated with vehicle
or 5 μM NVP-AEW541 (- or +, respectively), and cell
numbers determined as indicated. IGF-1 and MØCM
each significantly increased cell numbers after 48 and 72
hrs, while pharmacological inhibition of IGF-1R
signaling blocked IGF-1 and MØCM growth effects in
both neoplastic lines (Figure 7G, H). Parallel comparison
of MTS values indicated a highly significant correlation
between live cell numbers and relative MTS scores (r
2 =
0.7912 and 0.8201 for LM2 and JF32, respectively, p <
0.0001, data not shown). Furthermore, both IGF-1 and
MØCM increased the fraction of BrdU
+ LM2 cells 12-
24 hrs after treatment, corresponding with significantly
increased cell numbers (data not shown). These observa-
tions suggest that IGF-1, but not EGF, plays a major
role in macrophage stimulated neoplastic growth in
vitro, consistent with the elevated IGF-1 levels observed
in lung-tumor bearing animals in vivo.
MØCM stimulation of neoplastic growth is diminished
when IGF-1 content is decreased
In order to determine if IGF-1 was a molecular mediator
directly responsible for growth stimulated by MØCM, we
decreased MØCM IGF-1 content through two indepen-
dent avenues: immuno-depletion and siRNA interference.
MØCM was concentrated to contain ~3.5 ng/mL IGF-1,
and then incubated with control IgG (Con IgG) or a-IGF-
1 IgG coated resin, as described [39]. This procedure suc-
cessfully decreased MØCM IGF-1 levels to 40-50% of con-
trol (Figure 8A). When this IGF-1 depleted media was
added to LM2 and JF32 cells, growth stimulation was sig-
nificantly decreased compared to untreated MØCM or
IgG controls, which were identical (Figure 8B). In addition,
MH-S macrophage IGF-1 secretion was interrupted by
transfection with scrambled control (scr siRNA) or siRNA
constructs designed against mouse IGF-1 (a-IGF siRNA).
One a-IGF siRNA construct was more effective than the
scr siRNA, and significantly decreased MØCM IGF-1
levels to 25% of control (Figure 8C). The scr siRNA con-
struct decreased macrophage IGF-1 secretion to a lesser
extent (Figure 8C). Transfection reagents and conditions
were chosen to minimize cellular toxicity, and media IGF-
1 content significantly decreased when normalized to
MH-S viability (media IGF-1/MTS relative viability, data
not shown). Neoplastic growth reflected the level of IGF-1
in the media conditioned by siRNA-treated macrophages,
with all three groups differing significantly in JF32 cells
(Figure 8D). While scr siRNA-treated media did not signif-
icantly lower LM2 cell growth, the correlation of media
IGF-1 levels vs. LM2 proliferation was highly significant,
as in JF32 cells (Figure 8D-F). Taken together, these
experiments demonstrate that IGF-1 is responsible for the
majority of neoplastic growth stimulated by MØCM.
Combined MEK and PI3K inhibition blocks IGF-1 and
MØCM induced neoplastic proliferation by decreasing
cyclin D1 expression
IGF-1 stimulated neoplastic proliferation and mediated a
significant portion of macrophage-induced tumor cell
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Page 9 of 20growth in culture. To determine if MØCM and/or IGF-
1 were similarly blocked by MEK and PI3K inhibition,
LM2 and JF32 cells were treated with combinations of
MEK and/or PI3K inhibitors, in the presence of IGF-1
or MØCM. Analogous to previous results with macro-
phage co-culture, growth stimulated by either IGF-1 or
MØCM was blocked by combined inhibition of MEK
and PI3K, to a greater extent than either pathway by
itself (Figure 9A, B). Consistent with the proliferation
results, cyclin D1 content (a biochemical correlate of
lung cell proliferation [41]) was reduced by these inhibi-
tors (Figure 9C-E).
MØCM induced early increases in cRaf, Akt and GSK-
3b phosphorylation, and Erk1/2 phosphorylation peaked
at 24 hrs (Figure 9C, D). In both LM2 and JF32 cells,
increased Akt phosphorylation corresponded to more
phosphorylation of the Akt substrate, pGSK-3b (Figure
9H and 9I). Phospho-cRaf levels, another marker of Akt
activity, also increased in concert with heightened
increased Akt activity from 4-24 hrs; although p-cRaf
abruptly dropped at 48 hrs, pAkt and pGSK-3b levels
remained highly elevated (Figure 9F, H and 9I).
We observed reciprocal changes in the Erk and Akt
pathways in response to their respective enzyme
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Figure 7 Neoplastic proliferation stimulated by both IGF-1 and MØCM is additive, but unaffected by EGF. A-D: (A) LM2, (B) JF32, (C) E10
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Page 10 of 20inhibitors. In LM2 cells, MEK inhibition (by U0126)
suppressed early Erk1/2 phosphorylation while p-Akt
levels increased. Conversely, PI3K inhibition (by
LY294002) increased basal p-Erk1/2 levels at the
e x p e n s eo fp - A k t( 4h r st i m ep o i n t ;F i g u r e9 C ) .M E K
inhibition raised p-Erk1/2 and total Erk1/2 levels at 24
and 48 hrs, while PI3K inhibition caused a compensa-
tory increase in cellular p-Akt levels from 24-48 hrs.
JF32 cell growth was also suppressed by each drug;
although MEK inhibition did not affect p-Erk1/2 levels
at 4 hrs, p-Erk1/2 levels decreased at 48 hrs (Figure 9D).
PI3K inhibition stimulated Erk1/2 phosphorylation from
4-24 hrs, and increased Akt phosphorylation throughout
the treatment time-course (Figure 9G, H).
While each inhibitor decreased basal proliferation
rates (Figure 9A, B), combinations of kinase inhibitors
and MØCM increased cRaf, Erk1/2, Akt and GSK-3b
phosphorylation in an additive manner, with the highest
levels observed in cells treated with both kinase inhibi-
tors and MØCM ("U+L +”,F i g u r e9 C - I ) .T o t a la n dp -
cRaf, p-Akt and p-GSK-3b were each significantly higher
after 4-24 hrs of treatment in all groups receiving any
combination of drug and MØCM, and p-Erk1/2 levels
spiked after 24 hrs of treatment (Figure 9F-I). Either
inhibitor alone partially prevented the increase in cyclin
D1 in cells treated with MØCM; cells receiving both
inhibitors had the lowest cyclin D1 levels and were
unresponsive to MØCM-induced growth (Figure 9E).
Taken together, MØCM-induced neoplastic Akt and
Erk1/2 phosphorylation was magnified several-fold by
inhibitor treatment, dissociating kinase activity from
proliferation in drug-treated cells; however, cyclin D1
levels were suppressed by either drug alone, which cor-
responded to decreased cell proliferation.
As with MØCM, IGF-1 stimulated both Akt and Erk1/2
activities. Kinase activation was greatest within 4 hrs of
treatment, and remained elevated 48 hrs later, correspond-
ing with increased cyclin D1 expression (Figure 10A-E).
When treated with 2 ng/mL EGF, a concentration 1,000-
times higher than the amount of EGF in cell-conditioned
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Figure 8 MØCM IGF-1 content regulates the proliferation of treated neoplastic cells. A-B: Macrophage-conditioned media (MØCM) was
concentrated and immunoprecipitated against isotype control (Con IgG) or a-mIGF-1 IgG antibodies (a-IGF IgG). (A) Media IGF-1 content was
analyzed by ELISA, and (B) LM2 or JF32 cells were cultured in serum-free media with 0.5% BSA, with or without the MØCM generated in (A).
Relative growth was determined by MTS, and mean + SD plotted as fold-change from control, which was normalized to 1.0. Data was pooled
from at least 3 independent experiments. * P < 0.01 vs. Con IgG; ** P < 0.001 versus untreated cells, and ## P < 0.001 versus the Con IgG group
by 1-way ANOVA. C-D: (C) IGF-1 concentration in media conditioned by macrophages pre-treated with scrambled control siRNA (scr siRNA) or a-
IGF-1 siRNA construct, vs. naïve MØCM, was determined by ELISA; (D) LM2 or JF32 cells were cultured and relative cell number determined as in
(C). (C) ** P < 0.001 vs. naïve MØCM and ## P < 0.001 versus the scr-siRNA by 1-way ANOVA; (D) ** P < 0.001 vs. untreated cells; # P < 0.05 and
## P < 0.001 vs. the scr siRNA group; and &P < 0.001 vs. the MØCM group by 1-way ANOVA. E-F: Pearson correlation and linear regression of
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0.0001.
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Page 12 of 20media and 40-times higher than what is detected in BAL
fluid, Erk1/2 activity was not significantly elevated and Akt
levels were unaffected (Figure 10C, D). EGF may partially
stimulate Erk1/2 activity at supra-physiological levels, but
this was not sufficient to stimulate cellular growth. When
administered at cell-and tissue-relevant levels, IGF-1 sti-
mulated both Erk1/2 and Akt activation, elevated cellular
cyclin D1 content, and induced neoplastic proliferation.
Discussion
Our results suggest that inflammatory macrophages
directly stimulate lung tumor growth through increased
local production of IGF-1. We show that both naïve and
tumor-educated primary lung macrophages stimulate the
proliferation of lung epithelial cells in vitro;r e c o m b i n a n t
IGF-1 recapitulates this effect, and the degree of macro-
phage-induced growth stimulation correlates with media
IGF-1 levels. IL-4 stimulates primary lung macrophages to
produce significantly more IGF-1 in vitro.T u m o r - e d u -
c a t e dm a c r o p h a g e sp r o d u c em o r eI G F - 1o nap e r - c e l l
basis than naïve BAL macrophages, consistent with the
elevated levels of TH2-like cytokines reported in the lung
tumor microenvironment. Secretory products of macro-
phages stimulate neoplastic Erk1/2 and Akt activity,
increase cyclin D1 expression, and accelerate growth. Both
macrophage conditioned media (MØCM) and recombi-
nant IGF-1 stimulate neoplastic proliferation, which can
be ablated by the combined inhibition of MEK and PI3K.
Sustained changes in macrophage phenotype exacer-
bate several lung diseases, and alternative macrophage
activation is an early event in lung tumorigenesis
[6,42,43]. TH2 cytokine levels rise in AC-bearing mice
and human NSCLC patients, and alternative activation
resulting from TH2-like cytokines increases IGF-1 macro-
phage production [11,38,39,44]. Selectively removing
alternatively-activated macrophages reduced lung tumor
colonization in mice [45]. In agreement with these
reports, we show that in vitro IL-4 stimulation enhanced
IGF-1 production by primary BAL macrophages. Tumor-
educated BAL macrophages produced significantly more
IGF-1 than naïve macrophages, both basally and in
response to IL-4 stimulation. We previously found that
lung tumors recruit increasing numbers of macrophages
to the alveolar space [6]. Therefore, the lung tumor
environment contains not only more macrophages, but
macrophages with heightened IGF-1 production. Consis-
tent with this conclusion, BALF IGF-1 levels were > 3-
fold higher in lung tumor-bearing mice compared to
naïve littermates (Figure 6A-B).
While the role of primary lung macrophages in med-
iating lung cancer proliferation has not been previously
examined, the effects of co-cultured stromal cell types
on a Kras mutant mouse lung AC cell line (LKR-13)
was recently reported [18]. When cultured with media
conditioned by MH-S cells, proliferation of AC cells
increased significantly, in agreement with our observa-
tions. This study focused on the migration resulting
from the increased CXCL1 (KC) and IL-18 observed
under co-culture conditions, and did not determine if
exogenous KC or IL-18 stimulated neoplastic prolifera-
tion. They also found that MH-S conditioned media had
no effect on neoplastic colony formation in soft agar,
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Figure 10 IGF-1 stimulates Erk and Akt activities and elevates
cyclin D1 expression. A-B: (A) LM2 or (B) JF32 cells were cultured
in serum-free media, with or without 2 ng/mL mIGF-1 or mEGF, and
cell homogenates were probed for protein expression. C-E:
densitometry from western blot replicates from LM2 and JF32 cell
lines was combined, and presented as fold change (mean ± SEM)
from untreated vehicle control lanes at each time point. * P < 0.05,
** P < 0.01 and *** P < 0.001 versus control (Veh -) cells at each
time point by 2-way ANOVA.
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independent growth of two Kras mutant lung tumor-
derived cell lines, using two independent assays (Figure 1).
By fractionating MØCM, we demonstrate that the factors
responsible for stimulating neoplastic proliferation are 7-
11 kDa, making IL-18 (18 kDa) an unlikely candidate. KC,
on the other hand, is a potent 8 kDa chemokine. Based on
molecular weight alone, we cannot rule out KC as contri-
buting to the increased growth caused by MØCM; how-
ever, several lines of evidence make this unlikely. First,
both MH-S and primary naïve BAL macrophages stimu-
late neoplastic proliferation, but KC was undetectable in
media conditioned by MH-S macrophages [18] or primary
BAL macrophages isolated from naïve or lung-tumor bear-
ing animals (data not shown). Second, unlike IGF-1, KC
expression does not increase in alternatively activated
macrophages [11]; alternative activation increases IGF-1
production, and this stimulates neoplastic proliferation.
Lastly, although Zhong, et. al. examined an exhaustive
array of cytokines, they did not measure IGF-1 [18]; thus,
they did not evaluate the role of IGF-1 in mediating the
effects observed in their co-culture model. Our observa-
tions of lung macrophages complement previous reports
regarding stromal cell stimulation of neoplastic growth
and invasion, and expand upon them to demonstrate that
macrophage-derived IGF-1 accelerates neoplastic lung cell
growth in vitro. Macrophage IGF-1 may thus have a
pathological role in lung cancer.
Direct connections between lung macrophages and
AC progression in vivo are less clear than the well-
described interactions between macrophages and breast
cancer cells [14,16], or osteoclasts and oncolytic breast
cancer metastases [46]. Lung tumor cells over-expres-
sing IL-1b enhanced macrophage recruitment and
tumor angiogenesis when implanted into syngeneic mice
[19]. In our studies, BALF CSF-1 levels were nearly
undetectable while IL-1b levels were significantly higher
in tumor-bearing lungs vs. naïve (data not shown). How-
ever, recombinant IL-1b did not affect the proliferation
of neoplastic lung epithelial cells in vitro, either alone or
in combination with IGF-1. IL-1b also did not signifi-
cantly affect IGF-1 production by MH-S macrophages
(data not shown). Although not responsible for the
macrophage-induced neoplastic proliferation observed in
our studies, IL-1b stimulated macrophages produce
more pro-angiogenic factors, and this interleukin may
contribute to the increased numbers of macrophages in
tumor-bearing lungs [6,10,19].
In lung cancer therapy, anti-angiogenic or anti-inflam-
matory agents show widespread efficacy across many
cancer types, while inhibition of the EGF receptor
(EGFR) is mainly effective in the NSCLC sub-population
containing activating EGFR mutations [40,47]. EGFR-
mutant lung cancers eventually become resistant to
anti-EGFR therapies, and then progress rapidly [12,40].
One proposed mechanism for lung cancer resistance to
anti-EGFR therapy is the increased expression of other
EGFR family receptors and/or the IGF-1 receptor [48].
Similar to the well-described hetero-dimerization among
the EGF receptor family, IGF-1R can form functional
complexes with EGFR [12,48]. Unlike IGF-1R, EGFR
can be stimulated by numerous EGF-like factors, which
macrophages produce in a tissue and disease-specific
manner [10,14,49]. However, we show that: 1) BALF
EGF levels are very low and do not differ between naïve
and tumor-bearing lungs; 2) macrophages produce trace
amounts of EGF in vitro; and 3) EGF does not stimulate
neoplastic lung proliferation either alone or in combina-
tion with IGF-1 or MØCM (Figures 6, 7 and data not
shown). Combined, these observations indicate that EGF
is not involved in the macrophage-stimulation of pul-
monary epithelial growth in vitro, and argue against sig-
nificant lung macrophage EGF production in vivo.T h e
increased EGFR phosphorylation in primary mouse lung
tumors bearing Kras mutations that we previously
reported could result from IGF-1R/EGFR coupling and
trans-activation after IGF-1 stimulation [48,50]. Muta-
tions in EGFR and KRAS are mutually exclusive in both
human and murine NSCLC, and EGF stimulation would
n o tb ee x p e c t e dd r i v eKras mutant models of lung can-
cer [23,40,50]. A requirement for the IGF-1 receptor in
mediating lung cancer growth is consistent with other
reports that IGF-1 stimulates rapid anchorage-indepen-
dent growth in vitro, while IGF-1R inhibition slows
tumor growth in both animal xenograft studies [27] and
human clinical trials [12].
IGF-1R signals through numerous downstream path-
ways in which the intracellular kinases Erk1/2 and Akt
are frequently activated [12,48]. We have previously
determined that MEK inhibition induces a potent G1
phase arrest in neoplastic lung cell cycle progression in
vitro [51], and others have determined that blocking
both MEK and PI3K slows lung tumor growth in vivo
[25]. We show herein that MØCM-stimulated neoplastic
proliferation significantly increases cyclin D1 expression,
which is abrogated by the combined inhibition of both
MEK and PI3K. Sole inhibition of either MEK or PI3K
partially limits macrophage stimulation of LM2 and
JF32 growth to slightly different extents. While MØCM
modestly increases Erk1/2 and Akt activity, long-term
MEK and PI3K inhibition strikingly stimulates both
kinases in an additive manner with conditioned media
treatment. This increased kinase activity resulting from
MEK and PI3K inhibition, however, is no longer asso-
ciated with changes in cyclin D1, as combined inhibition
resulted in the highest levels of Akt activity, but lowest
levels of cyclin D1 expression ("U + L"; Figure 9E and
9H). Compensatory Akt or Erk activation in response to
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sive cross-talk that exists among MAPK pathways,
where inhibition of any single mediator results in exag-
gerated and/or sustained signaling through an alternate
pathway [32,34,52,53]. Indeed, when the MEK pathway
was inhibited in LM2 cells, early p-Akt activity
increased, while PI3K inhibition increased p-Erk1/2 (4
hrs: Figure 9C). Akt is hyper-phosphorylated with 24 hrs
of treatment with either MEK or PI3K inhibitor, and
this hyper-activated Akt sustains 5-10 higher levels of p-
GSK-3b and p-cRaf for at least 48 hrs. Erk1/2 phosphor-
ylation is also stimulated by drug treatment, which
peaks at 24 hrs and rapidly declines by 48 hrs. Consis-
tent with our observations, continuous hyper-activation
of Akt or Erk1/2 induces cytostasis or even apoptosis in
some tissues, while more modest Erk1/2 activation
drives Kras mutant tumor cell proliferation [34,40,51].
While our studies demonstrate that MØCM and IGF-1
stimulated neoplastic growth is affected similarly by
MEK and PI3K inhibition, further studies in genetically-
silenced or kinase-mutant cell lines are required to
determine the discrete cellular mechanisms necessary
for growth factor-stimulated neoplastic proliferation.
Kras mutant lung tumors may rely on growth factor
stimulation in vivo to regulate binding partner localiza-
tion and activation. Kras can only efficiently trigger pro-
liferation by recruiting partner kinases like cytosolic Raf
(cRaf/Raf-1) to the plasma membrane, where cRaf is
phosphorylated and activated by ligand-bound growth
factor receptors [33,54]. By phosphorylating mutant
Kras-bound cRaf, growth factors can potently engage
the ras-Raf signaling cascade, which deactivates slowly
due to decreased GTPase activity of mutant Kras
[24,54]. Akt phosphorylates cRaf at S259, which creates
a binding domain for 14-3-3 protein family members
[32,33]. 14-3-3 binding is required to inactivate cRaf, as
p-S259 alone does not affect cRaf activity. However,
mutant Kras can displace 14-3-3 from the p-S259 region
of cRaf [33]. Thus, active Akt could phosphorylate and
inactivate cRaf, leading to decreased Erk1/2 signaling,
but cells with mutant Kras can bypass this regulatory
mechanism and maintain high cRaf activity [33,54].
Consistent with these reports, we observe significant
increases in neoplastic Akt, cRaf and Erk1/2 phosphory-
lation, suggesting that these Kras mutant cells bypass
Akt-mediated MEK pathway inactivation (Figures 3 and
9). Due to the complex interactions between Erk and
Akt, IGF-1 stimulated growth regulation in Kras-mutant
NSCLC cells should be the subject of future
investigation.
Conclusions
In summary, we have identified IGF-1 as one factor pro-
duced by alveolar macrophages that directly stimulates
neoplastic lung proliferation in vitro.T h e s ef i n d i n g s ,i n
combination with correlations between macrophage
numbers, activation state and IGF-1 levels in vivo, imply
that IGF-1 mediates macrophage stimulation of NSCLC
growth. This additional evidence links previous observa-
tions of macrophage depletion to tumor growth sup-
pression. Macrophages are crucial for the progression of
numerous cancers, including lung cancer, and IGF-1 has
long been associated with resistance to chemotherapy
and increased neoplastic proliferation.
Our results suggest that current anti-growth factor
therapy could be augmented by removing the stromal
source of neoplastic growth stimulation, in addition to
blocking discrete elements of downstream signal trans-
duction. This may be an effective strategy for the treat-
ment of lung cancer and other diseases in which
macrophage recruitment is associated with aberrant tis-
sue proliferation.
Methods
Mice
Male A/J mice (4-6 wks old) were purchased from the
Jackson Laboratory (Bar Harbor, ME), housed on hard-
wood bedding with 12 hr light/dark cycles, and fed Har-
lan Teklad 22/5 rodent chow ad libitum (Harlan,
Madison, WI) at the Center for Comparative Medicine
in the University of Colorado, Anschutz Medical Cam-
pus. Procedures were approved by the Institutional Ani-
mal Care and Use Committee of the University of
Colorado.
Isolation of lung protein exudates and alveolar
macrophages
Primary alveolar macrophages and lung protein exudates
were isolated by bronchoalveolar lavage (BAL) from
male A/J mice 24-32 wks after a single i.p. injection of
10 mg/g ethyl carbamate (urethane; Alfa Aesar; Hey-
sham, Lancashire. U.K.) or 0.9% NaCl vehicle control, as
previously described [6,55]. This dose of urethane
induces multiple lung tumors in A/J mice, which are
mainly adenomas at 24 wks and progress to AC from
24-42 wks. BAL macrophages from control animals are
considered “naïve”, while macrophages isolated from
lung tumor-bearing mice are “tumor-educated” [14].
Generation of JF32 cells from primary lung tumor isolates
Thirty-two wks after urethane injection, male A/J lung
tumors were resected from the lung under a dissecting
microscope. Fifty mg of tumor tissue was placed onto a
sterile Pyrex petri dish, finely chopped in 0.2 mL PBS
with a sterile razor, and the resulting suspension added
to a Krebs-Ringer buffered solution containing 10 U/mL
Dispase 10 U/mL collagenase I (Worthington, Lake-
wood, NJ.). The tumor suspension was digested with
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terminated by adding an equal volume of 20 mM
EDTA. The tumor suspension was then passed twice
through a 20 ga syringe needle, and filtered to create a
single cell suspension of tumor cells, as described for
the isolation of primary Clara cells [56,57]. These tumor
cells were washed 3-times in 10% FBS (Hyclone; Logan,
UT) MEM-a (Invitrogen; Carlsbad, CA), collected by
centrifugation, and their viability determined by trypan-
blue (Sigma-Aldrich; St. Louis, MO) exclusion using a
hemocytometer. The primary tumor isolates were > 90%
viable by this method. Twenty thousand cells per well
were plated in 1% FBS MEM-a on Matrigel-coated 6-
well plates (Fisher; Waltham, MA). The primary tumor
cell cultures were maintained for 4 weeks, and MEM-a
media containing 1% FBS changed once weekly. For
three weeks, there was little morphological change in
colony size or number, and then actively proliferating
colonies were observed. Two adherent colonies were
removed (using a trimmed pipette tip), designated
“JF32a” and “JF32b”, plated onto standard 100 mm tis-
sue culture-treated plates, and cultured as described
below. Exon 2 of the Kras gene was sequenced as pre-
viously described [50], and Q61R Kras mutations
detected in both JF32a and b, consistent with our pre-
viously published report of Kras mutation incidence in
urethane-induced mouse lung tumors [50].
Cell culture
The non-tumorigenic, mouse type II pneumocyte-
derived epithelial cell line (E10) was used to represent
non-transformed lung epithelium in vitro.T os t u d y
the interactions of tumor cells with macrophages,
three neoplastic mouse lung cell lines were used: the
newly generated JF32a cells (hereafter “JF32”); LM2,
previously derived from a urethane induced lung
tumor in A/J mice; and E9, a spontaneous transfor-
mant of E10 cells [57]. Culture of all cell lines was
previously described; JF32 cells were maintained like
the LM2 cell line [21,57]. To study the in vitro effects
of immune mediators on epithelial cells, MH-S
macrophages (American Type Culture Collection;
Manassas, VA), an alveolar macrophage cell line iso-
lated from a BALB/c mouse [58], or primary BAL
macrophages were used. All macrophages were main-
tained in RPMI 1640 (Invitrogen) according to ATCC
guidelines for the MH-S cell line. All cells were
cultured in a humidified atmosphere of 5% CO2 in
ambient air at 37°C, and routinely screened for Myco-
plasma contamination (MD Biosciences Inc; St. Paul,
MN). Where indicated, 2-50 ng/mL recombinant
mouse IGF-1 (R&D Systems, Inc.; Minneapolis, MN.)
and/or EGF (eBioscience, Inc.; San Diego, CA) were
added to epithelial cultures.
Anchorage-independent culture
LM2 and JF32 cells were suspended in 0.5% low-melting
point agarose (Ultra-pure LMP agarose, Invitrogen) in
MEM-a media containing 0.5% BSA (Sigma), and plated
at 1,000 cells/well into 12 well plates with a pre-coated
base layer of 1% agar (Sigma), and a top layer of 0.75%
LMP agarose. Once weekly, cells were fed with 0.5 mL
MEM-a + 0.5% BSA or macrophage-conditioned media
(with 0.5% BSA, described below). After 5-6 wks of
growth, colony number (clumps of ≥ 10 cells) was deter-
mined under 20× magnification with a bright-field
inverted microscope (Nikon Instruments Inc, Melville,
NY). Alternatively, neoplastic cells were suspended in
MEM-a media containing 0.5% BSA, and plated at 3,000
cells/well onto ultra-low attachment 6-well culture plates
(Costar, Corning, NY). Cells were fed once weekly with 1
mL MEM-a + 0.5% BSA or macrophage-conditioned
media. After 3 wks, the contents of each well were
removed with a pipette, and cells pelleted by 5 min. centri-
fugation at 600 × g. Cells were resuspended in 1.5 mL
Accutase (Sigma), and incubated for 20 min. at 37°C to
create a single-cell suspension. Equal volumes of cell sus-
pension were added to 0.4% Trypan-blue solution (Sigma),
and live vs. dead cells ascertained using a hemocytometer.
Macrophage co-culture and conditioned media
Epithelial cell lines were plated onto tissue culture-trea-
ted plates (Costar). Macrophages were plated onto 0.4
μm pore Transwell inserts (Becton Dickinson, Franklin
Lakes, NJ) to allow diffusible signals to exchange during
co-culture while preventing physical contact. Epithelial
cells and macrophages were plated separately in media
containing 10% FBS and allowed to equilibrate over-
night. All co-culture systems consisted of macrophages
co-incubated with epithelial cells at a 1:5, macrophage
to epithelial cell ratio (2-4 wells/condition). Co-culture
was initiated by replacing the original media with fresh
serum-free MEM-a + 1% BSA media (SF MEM-a), and
inserting the macrophage-containing Transwells into
wells containing epithelialc e l l s .T os t u d yt h ed i r e c t
effects of macrophage-derived molecules on epithelial
cells, media conditioned by primary BAL macrophages
was generated by culturing 100,000 macrophages in 24-
well plates in 1 mL media for 24 hrs. This macrophage-
conditioned media (MØCM) was then added to epithe-
lial cell-containing wells at a 1:1 ratio with fresh media.
For additional experimental analysis, SF MEM-a media
was conditioned by MH-S macrophages at 1 million
macrophages/mL for 24 hrs, and added to cells as above.
Conditioned media fractionation and IGF-1 immuno-
depletion
MØCM from MH-S macrophages was collected and fil-
tered through Microcon 0.5 mL volume spin filters
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offs (m.w.c.o.) of 3, 10 and 30 kDa, as indicated. Each
column was rinsed 2× with PBS, and then 500 μLo f
MØCM or control SF MEM-a media applied and col-
umns centrifuged at 11,000 × g @ 10°C until only ~50
μL remained. The concentrated media was removed and
added to LM2 containing wells in 500 μLo ff r e s hS F
MEM-a. IGF-1 was depleted from MØCM following
the method described by Wynes, et. al., with several
modifications [39]. Conditioned media was first concen-
trated 4-times against a 3,000 kDa m.w.c.o. Amicon fil-
ter using a nitrogen pressure filtration chamber
(Millipore) to yield a final IGF-1 concentration of 3-4
ng/mL. This MØCM concentrate was rotated for 2 hrs
with 6 μgo fa-mIGF-1 IgG antibodies, consisting of a
1:1:1 w/w ratio of: MAB791, AF791 (R&D systems, Inc)
and sc-1422 (Santa Cruz Biotechnology, Inc, Santa Cruz,
CA). As an IgG control, 6 μg of goat IgG a-COX-1 anti-
body (sc-1754, Santa Cruz) was used. Fifty μL of protein
G-coated magnetic resin, prepared and washed as direc-
ted (DynaMax; Invitrogen), was added to the media +
antibody solution, and rotated for 1 hr. The resin was
separated from the solution with a Dynal bench-top
magnet (Invitrogen) and discarded, while the MØCM
was transferred to a sterile eppendorf tube. This process
was repeated with fresh antibody prior to cell treatment.
MH-S siRNA transfection
MH-S macrophages were transfected with siRNA tar-
geted against murine IGF-1 according to manufacturer
instructions for murine J774.1 macrophage transfection
(Qiagen Inc, Valencia, CA), and then optimized for
MH-S transfection as described below. Three a-IGF-1
siRNA constructs, SI01073996, SI01073982 and
SI01073989 (Qiagen; http://www.qiagen.com/geneglobe),
were evaluated for IGF-1 knockdown, as determined by
IGF-1 levels in conditioned media. Knockdown effi-
ciency was compared against naïve (untransfected) and
AllStars negative control (scrambled siRNA) transfected
cells; the AllStars negative control has no known homol-
ogy to any mammalian gene (Qiagen). Constructs “...96”
and “...82” were no more effective than the negative con-
trol, while “...89” (hereafter referred to as “a-IGF-1
siRNA”) effectively knocked down IGF-1 release into
culture media. The transfection reagent HiPerFect (Qia-
gen) exhibited low toxicity and was used to establish
transfection conditions that maintained ≥ 80% viability
in transfected cells vs. naïve. In brief, 150,000 MH-S
macrophages/well were suspended in 200 μL of 10%
FCS supplemented RPMI in 24-well plates and allowed
to incubate as described above for 1-2 hrs. For each
well, siRNA (1.5 μLo fa2 0μM stock solution) was
added to 100 μL of serum-free RPMI and vortexed prior
to addition of 4.5 μL HiPerFect transfection reagent.
After 4 hrs, 150 μL of 10% FCS RPMI was added; 12
hrs later another 150 μL of 10% FCS RPMI was added.
After 48 hrs, the transfection media was removed and
replaced with SF MEM-a +0 . 5 %B S A ,w h i c hM H - S
macrophages conditioned for 24 hrs. Successful IGF-1
depletion was monitored by ELISA, as described.
Cell proliferation and viability
Relative cell number was determined by 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium assay (MTS;CellTiter 96
®
One AQueous,P r o m e g a ;M a d i s o n ,W I )a c c o r d i n gt o
manufacturer’s instructions, and measured spectropho-
tometrically at Abs490 nm (Vmax, Molecular Devices;
Sunnyvale, CA). Additionally, cells were trypsinized, col-
lected and counted with a hemocytometer after trypan-
blue staining. All cell counts were normalized to control
values for each cell line or treatment group, unless
otherwise indicated.
Determination of IGF-1 and EGF levels
IGF-1 and EGF were separately measured in biological
samples by enzyme-linked immunosorbant assay
(ELISA) in a 96-well format, according to the manufac-
turer’sd i r e c t i o n s( R & DS y s t e ms, Inc.), and measured
spectrophotometrically at Abs450 nm with wavelength
correction set to Abs550 nm. All samples were diluted to
be within the middle 60% of the 8-point standard curve,
and concentrations calculated from log-transformed
absorbance values, as recommended. In addition to stan-
dard curves, every plate contained an independent cali-
brator sample that tested within the range provided.
Immunoblotting
Epithelial cell protein lysates were harvested after 48 hrs
co-culture with MH-S macrophages (+), empty inserts
(-, controls) or at the indicated time after conditioned
media or growth factor addition (+), and compared to
control wells without MØCM (-) as described [21,50],
with the following modifications. Protein (5-10 ug/lane)
was applied to 4-20% Tris-SDS Criterion gels (Bio-Rad,
Hercules, CA), and separated proteins electro-
transferred onto Immobilon-P PVDF membranes (Milli-
pore). The membranes were blocked for 30 min. at
room temperature in 100 mM Tris-buffered saline pH
7.4 with 0.1% Tween-20 (TBST) supplemented with the
indicated concentration of non-fat dry milk, and incu-
bated overnight at 4°C with primary antibodies diluted
in blocking buffer with milk or bovine serum albumin
(BSA; Sigma), as described in Table 1 [51]. After wash-
ing, blots were incubated with horseradish-peroxidase
conjugated secondary antibodies at the indicated dilu-
tion for 1 hr at room temperature (Table 1), and protein
bands were visualized by chemiluminescence on X-ray
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phospho-specific proteins were applied to freshly trans-
ferred membranes. After detection, membranes were
stripped with 1 M Tris-HCl (pH 6.7) buffer containing
2% SDS and 0.86% 2-mercaptoethanol (Fisher) in a 50°C
hybridization oven for 60 min., and probed with antibo-
dies against total protein levels as indicated. Equal pro-
tein loading was confirmed by b-actin levels and
Coomassie gel staining (Fisher). Band density was quan-
tified by Un-Scan-It software (Silk Scientific, Orem,
UT), and values normalized either to b-actin or relevant
total protein bands on each PVDF membrane.
Drug treatment of cells
To selectively block activation of the Erk and Akt signal-
ing pathways, selective inhibitors of MEK (U0126; Pro-
mega) and PI3K (LY294002; Cell Signaling Technology,
B e v e r l y ,M A )w e r eu s e da t5μMa n d1 0μM, respec-
tively [37]. Drugs were dissolved in DMSO in amber
tubes immediately prior to use, and added in SF MEM-
a to cells cultured alone, with MH-S macrophages, with
MØCM, or with recombinant growth factors for 72 hrs.
The concentration of DMSO in all experiments never
exceeded the vehicle control of 0.05%. To selectively
block IGF-1R signaling, NVP-AEW541 (Cayman Chemi-
cal Company; Ann Arbor, MI) was directly dissolved in
to 0.5% BSA-supplemented MEM-a media, and added
to cell-containing wells at a final concentration of 5 μM.
Statistical analysis and estimation
To estimate the size of the MØCM factor responsible
for stimulating neoplastic proliferation, we derived a
function describing the extent of tumor cell growth (y)
in terms of the size of molecules predicted to be con-
tained in isolated fractions of conditioned media (x).
The percent retention on size-exclusion columns (as
fractions of the amounts loaded) vs. protein size (kDa)
on each size m.w.c.o. column was provided by the
manufacturer (Millpore) for six recombinant proteins of
varying size. The resulting data set was plotted as per-
cent retained vs. protein size, and the least complex
“best-fit” equation was obtained using non-linear regres-
sion with SigmaPlot 2001 ver 7.101 (SysStat Software
Inc., San Jose, CA). The extent that total, unfractionated
MØCM stimulated LM2 proliferation was normalized to
100%. The extent that each retentate fraction stimulated
LM2 growth was similarly calculated to determine the
remaining percent of “growth stimulating ability” after
filtration, as compared to unfractionated MØCM. The
percent of growth stimulus remaining was equated to
the percentage of protein standard retained, and the
resulting protein size estimate calculated from the best-
fit equation.
Densitometry measurements are presented as means ±
SEM, and all other measurements as means ± SD [59].
Differences between conditions at specific time points
were examined using Student’s unpaired t-test when
comparing only two groups, with Welch’s correction for
unequal variance when appropriate. For multiple com-
parisons, one-way and two-way ANOVA were used to
compare interactions between co-culture conditions and
proliferation rates as recommended [60,61]. The Bonfer-
roni correction was used for multiple comparisons during
ANOVA analysis. Correlation was performed using the
Pearson method, and the corresponding linear regression
plotted. All statistical tests for significance and correla-
tion were performed using GraphPad Prism version 4.02
(GraphPad Software; San Diego, CA.); differences were
considered statistically significant when P < 0.05.
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extracellular-regulated kinase 1/2; GM-CSF: granulocyte-monocyte colony
stimulating factor; GSK-3β: glycogen synthase kinase 3β; IGF-1: insulin-like
factor 1; IL-1β: interleukin-1β; KC: keratinocyte-derived chemokine; MEK:
Table 1 Western blot antibody dilution
Antibody
Target
Blocking/Antibody Dilution
Buffer*
Primary Antibody
Dilution†
Secondary Antibody
Dilution
Antibody Source (1°/
2°)‡
p-cRaf (S259) TBST + 5% milk 1:2,000 (5% BSA) 1:10,000 goat anti-rabbit CST/CST
c-Raf TBST + 5% milk 1:1,000 (5% BSA) 1:10,000 goat anti-rabbit CST/CST
pErk1/2 (Y204) TBST + 2% milk 1:1,000 1:20,000 goat anti-mouse S.C./S.C.
Erk1/2 TBST + 2% milk 1:50,000 1:40,000 goat anti-rabbit S.C./S.C.
pAkt (S473) TBST + 5% milk 1:4,000 (5% BSA) 1:10,000 goat anti-rabbit CST/CST
Akt TBST + 5% milk 1:10,000 (5% BSA) 1:20,000 goat anti-rabbit CST/CST
pGSK-3b (S9) TBST + 5% milk 1:1,000 (5% BSA) 1:10,000 goat anti-rabbit CST/CST
panGSK-3b TBST + 5% milk 1:2,000 (5% BSA) 1:10,000 goat anti-rabbit CST/CST
Cyclin D1 TBST + 5% milk 1:2,000 (5% BSA) 1:10,000 goat anti-rabbit CST/CST
b-actin TBST + 2% milk 1:100,000 1:100,000 goat anti-mouse Sigma/S.C.
*TBST, 100 mM Tris-buffered saline pH 7.4 with 0.1% Tween-20. † BSA, bovine serum albumin. ‡ Primary (1°) and secondary (2°) antibodies were obtained from
Sigma, Santa Cruz Biotechnology, Inc. (S.C.; Santa Cruz, CA) and Cell Signaling Technology (CST).
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Page 18 of 20mitogen-activated: extracellular regulated kinase (MAP2K); MØCM:
macrophage-conditioned media; pan-: total levels; NSCLC: non-small cell
lung cancer; PI3K: phosphoinositide 3-kinase.
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